Tabriz University of Medical Sciences About    Newsletter    Contact Us    Create Account    Log in  
Advanced Pharmaceutical Bulletin
ISSN: 2228-5881      eISSN: 2251-7308  
Export citation
Reference Manager

Cite by
Google Scholar

Article History
Submitted: 16 Nov 2012
Revised: 27 Nov 2012
First published online: 07 Feb 2013

Article Access Statistics
Abstract Page Views: 231
PDF Downloads: 116
Full Text Views: 0

Adv Pharm Bull. 2013;3(1):203-206 doi: 10.5681/apb.2013.033
PMID:24312836        PMCID:PMC3846046

Dose-Dependent Effect of Flouxetine on 6-OHDA-Induced Catalepsy in Male Rats: A Possible Involvement of 5-HT1A Receptors

Original Research

Hamdolah Sharifi, Alireza Mohajjel Nayebia * , Safar Farajnia

Purpose: Progressive loss of dopaminergic neurons of the substantia nigra pars compacta (SNc) in Parkinson’s disease (PD) leads to impairment of motor skills. Several evidences show that the role of serotonergic system in regulation of normal movement is pivotal and mediates via 5-HT1A receptors. Our previous study has shown that fluoxetine in acute injections able to attenuate catalepsy in 6-hydroxydopamine (6-OHDA)-lesioned rats. Since drugs are used chronically in clinic, in this study we attempted to evaluate effect of chronic administration of fluoxetine on 6-OHDA-induced catalepsy. Methods: Catalepsy was induced by unilateral infusion of 6-OHDA (8 µg/2 µl/rat) into the central region of SNc and assayed by using bar-test. Fluoxetine (1, 2.5, 5 and 10 mg/kg) was injected intraperitonealy (ip) for 10 days and its anti-cataleptic effect was assessed at the 10th day. Results: Fluoxetine in high doses (5 and 10 mg/kg) worsened 6-OHDA-induced catalepsy while it had anti-cataleptic effect at the dose of 1mg/kg. The anti-cataleptic effect of fluoxetine (1mg/kg) was reversed by co-administration with NAN-190 (0.5 mg/kg, ip), as a5-HT1Areceptor antagonist. Conclusion: According to the results it can be concluded that fluoxetine has anti-cataleptic effect in parkinsonian rats only at low doses, whereas at higher doses it worsens catalepsy. It’s anti-cataleptic effect is exerted through affecting on 5-HT1Areceptors. However, at high doses other mechanisms may be involved. Further clinical studies are needed to prove it’s possible clinical application as an adjuvant therapy in reducing catalepsy of PD.

First name  
Last name  
Email address  
Security code

This Article

Google Scholar
Articles by Sharifi H
Articles by Mohajjel Nayebia A
Articles by Farajnia S

Articles by Sharifi H
Articles by Mohajjel Nayebia A
Articles by Farajnia S

Similar articles in PubMed

Share this article!

Press Manuscript Online. Powered by MAADRAYAN